TC
HRTX icon

TFS Capital’s Heron Therapeutics HRTX Stock Holding History

TFS Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-30,057
Closed -$370K – 1110
2014
Q2 		$370K Buy
30,057
+16,406
+120% +$196K 0.03% 757
2014
Q1 		$190K Buy
+13,651
New +$182K 0.01% 1203

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

TFS Capital's HRTX Position: Q3 2014 in Review

TFS Capital sold out of Heron Therapeutics (HRTX) in Q3 2014, closing a stake of 30,057 shares — an estimated $370K sold.

TFS Capital first reported a position in HRTX in Q1 2014 and held it in 2 quarters. The position peaked at $370K in Q2 2014. 59 funds tracked by Wall St. Rank hold HRTX as of Q3 2014.

  • TFS Capital reported no remaining Heron Therapeutics position as of Q3 2014 after selling out during the quarter.
  • TFS Capital sold 30,057 Heron Therapeutics shares in Q3 2014, an estimated $370K.
  • TFS Capital first reported a position in Heron Therapeutics in Q1 2014 and held it in 2 quarters.
  • TFS Capital's Heron Therapeutics position peaked at $370K in Q2 2014.
  • 59 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2014.

Based on TFS Capital's 13F filing for Q3 2014, filed 6 Nov 2014.